1st Quarter - Report

TCH GROUP, LLC for SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC )

Firm
Client
Income
$20,000
Expenses
—

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Copyright/Patent/Trademark CPT

All provisions of S369 "Protecting Access to Affordable Generic Drugs Act of 2009"; and HR 1706 "Protecting Consumer Access to Generic Drugs Act of 2009"; all provisions of S515 "The Patent Reform Act of 2009" and HR 1260 "The Patent Refrom Act of 2009"; HR 4872, "Health Care & Education Reconciliation Act of 2010" provisions related to patent settlements.

Foreign entity interest: sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4872 (111th), H.R. 1260 (111th), H.R. 1706 (111th)

Medicare/Medicaid MMM

Issues related to vaccine administration payment under the Medicaid program.

Foreign entity interest: sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Taxation/Internal Revenue Code TAX

Extension of the R&D tax credit and all such provisions in HR4213, "American Workers, State, and Business Relief Act of 2010"; HR422 "To amend the Internal Revenue Code of 1986 to extend the research credit through 2010 and to increase and make permanent the alternative simplified research credit"; and S1203 "Grow Research Opportunities with Tax Credits' Help Act" or "GROWTH Act".

Foreign entity interest: sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 422 (111th), H.R. 4213 (111th)

Health Issues HCR

HR3692 "To provide affordable, quality health care for all Americans and reduce growth in health care spending, and for other purposes"; HR 4872 "Health Care and Education Reconciliation Act of 2010"; HR3590 "The Patient Protection and Affordable Care Act"- provisions related to follow-on biologics, comparative effectiveness research, 340B programs and the Independent Payment Advisory Board; issues related to prescription drug safety and heparin; issues related to cancer awareness and access to treatment.

Foreign entity interest: sanofi-aventis U.S. inc. is an international company with headquarters in Paris, France.

LobbyistCovered position, as disclosed
JOHN HOLSCLAW —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3590 (111th), H.R. 4872 (111th), H.R. 3692 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.